REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Convenient oral dosing for Rd.

Continue treatment until disease progression or unacceptable toxicity.

REVLIMID® 25 mg Capsule


25 mg on Days 1-21 of repeated 28-day cycles

  • Capsule shown not actual size.

In clinical trials, dexamethasone was dosed at 40 mg on Days 1, 8, 15, and 22 of repeated 28-day cycles.*

  • *Patients >75 years received 20 mg of dexamethasone once daily on Days 1, 8, 15, and 22 of repeated 28-day cycles.

REVLIMID can be used in all levels of renal impairment.

  • Since REVLIMID is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID are recommended to provide appropriate drug exposure in patients with renal impairment and in patients on dialysis


REVLIMID® Dosing Instructions for Renal Impairment

Capsules shown not actual size.

  • For CrCl 30-60 mL/min: Consider escalating the dose to 15 mg after 2 cycles if the patient tolerates the 10 mg dose of REVLIMID without dose-limiting toxicity
  • After initiation of REVLIMID therapy, subsequent REVLIMID dose increase or decrease is based on individual patient treatment tolerance
Dosing for Patients with Renal Impairment

See recommendations for renally impaired patients, including patients on dialysis.

Dose Modifications for Adverse Events

See downloadable dose modifications for select adverse events.

Learn More
Dosing Guide

View the recommended dosing schedule and dose modifications.


Important Dosing Information.

  • The capsules should not be opened, broken, or chewed
  • REVLIMID is primarily excreted unchanged by the kidney. Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function
  • Monitor CBCs every 7 days (weekly) for the first 2 cycles, on Days 1 and 15 of Cycle 3, and every 28 days (4 weeks) thereafter
  • Treatment is continued or modified based on clinical and laboratory findings
  • Dose modification guidelines are recommended to manage Grade 3/4 neutropenia or thrombocytopenia
  • For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at next lower dose level when toxicity has resolved to ≤Grade 2
  • Patients may require dose interruption and/or reduction
  • Patients may require the use of blood product support and/or growth factors

Help patients stay on therapy
with dose modifications.

  • Until disease progression or unacceptable toxicity.


Grade 3/4 Hematologic Toxicities in REVLIMID®

For non-hematologic Grade 3/4 AEs, hold treatment, and after resolution to ≤Grade 2, restart at next lowest dose.

  • AE, adverse event; ANC, absolute neutrophil count; CBC, complete blood count; CrCl, creatinine clearance; G-CSF, granulocyte colony stimulating factor; MM, multiple myeloma; Rd, REVLIMID + dexamethasone.

Reference: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp.

Learn about the importance of continuous treatment.

View Continuous Treatment